Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: A prospective randomized pilot study

Journal of Hepatology

Volumn 56, Issue 1, 2012, Pages 299-300

  Shimada, Masahiko ^a   Yoshida, Shuhei ^a,b   Masuzaki, Ryota ^b   Schuppan, Detlef ^b  

^a TMG Asakadai Central General Hospital   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PITAVASTATIN; RIBAVIRIN; VIRUS RNA;

DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LETTER; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG SYNERGISM; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PILOT PROJECTS; PROSPECTIVE STUDIES; QUINOLINES; RANDOM ALLOCATION; RIBAVIRIN; VIRAL LOAD;

EID: 83555176098     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.04.024     Document Type: Letter

References (13)

1. S.A. Harrison, L. Rossaro, K.Q. Hu, K. Patel, H. Tillmann, and S. Dhaliwal Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy Hepatology 52 2010 864 874
2. M. Ikeda, K. Abe, M. Yamada, H. Dansako, K. Naka, and N. Kato Different anti-HCV profiles of statins and their potential for combination therapy with interferon Hepatology 44 2006 117 125 (Pubitemid 44049145)
3. J.G. O'Leary, J.L. Chan, C.M. McMahon, and R.T. Chung Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial Hepatology 45 2007 895 898 (Pubitemid 46631558)
4. T. Bader, J. Fazili, M. Madhoun, C. Aston, D. Hughes, and S. Rizvi Fluvastatin inhibits hepatitis C replication in humans Am J Gastroenterol 103 2008 1383 1389 (Pubitemid 351813920)
5. H. Sezaki, F. Suzuki, N. Akuta, H. Yatsuji, T. Hosaka, and M. Kobayashi An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads Intervirology 52 2009 43 48
6. R. Moucari, T. Asselah, D. Cazals-Hatem, H. Voitot, N. Boyer, and M.P. Ripault Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis Gastroenterology 134 2008 416 423 (Pubitemid 351181308)
7. T. Asselah, L. Rubbia-Brandt, P. Marcellin, and F. Negro Steatosis in chronic hepatitis C: why does it really matter? Gut 55 2006 123 130 (Pubitemid 41820647)
8. M. Romero-Gomez, M. Del Mar Viloria, R.J. Andrade, J. Salmeron, M. Diago, and C.M. Fernandez-Rodriguez Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641 (Pubitemid 40585366)
9. R.Y. Mukhtar, J. Reid, and J.P. Reckless Pitavastatin Int J Clin Pract 59 2005 239 252 (Pubitemid 40331227)
10. H. Ahmad, and A. Cheng-Lai Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia Cardiol Rev 18 2010 264 267
11. M. Ikeda, and N. Kato Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon J Pharmacol Sci 105 2007 145 150 (Pubitemid 350106803)
12. H. Moriguchi, R.T. Chung, and C. Sato An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells Hepatology 51 2010 351 352
13. H. Moriguchi, R.T. Chung, and C. Sato New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells Hepatology 51 2010 344 345 [author reply 345]